Summary
The EU Pharma Impacts is an innovative information source designed to provide readers with analytical updates on the changing landscape of EU regulations for medicinal products and medical devices in an expert-produced and easy to grasp one-page format with special emphasis on the implications for the pharmaceutical and medical device industries. Key features of EU Pharma Impacts are:
- Written by experts on EU pharma and pharmaceutical affairs having among them a former head of a National Medicines Agency, executives from European pharmaceutical industry trade organizations and pharma researchers
- EU Pharma Impacts content is designated for both customers in the key regulatory regions like North America and Japan, and for users across the enlarging European Union
- Each release of the EU Pharma Impacts contains a characteristic highlighted text box describing the impact on the pharmaceutical industry - expected to results from the newly introduced requirements, decisions and activities in the EU
- EU Pharma Impacts reflect published documents, statements and press releases by European Medicines Agency (EMEA), European Commission (especially F2 Unit "Pharmaceuticals" at DG "Enterprise and Industry"), European Council, European Court of Justice, European Directorate for Quality of Medicines (EDQM), and other relevant EU bodies
- EU Pharma Impacts are accompanied by mini English-language Glossary of the terms and definitions related to the EU pharmaceutical affairs
- Additional value-added features are the summaries of otherwise quite lengthy documents, list of the targeted professionals, current and future legal status of the document, links to the original sources and thumbnail of the documents.
Together these solutions help the pharmaceutical professionals outside EU to keep abreast with the key developments and their potential implications.
|
